Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) and Tiziana Life Sciences (NASDAQ:TLSA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.
Institutional and Insider Ownership
62.6% of Tectonic Therapeutic shares are owned by institutional investors. 38.0% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations for Tectonic Therapeutic and Tiziana Life Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tectonic Therapeutic | 1 | 0 | 5 | 1 | 2.86 |
| Tiziana Life Sciences | 1 | 0 | 0 | 0 | 1.00 |
Earnings & Valuation
This table compares Tectonic Therapeutic and Tiziana Life Sciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tectonic Therapeutic | N/A | N/A | -$57.98 million | ($3.86) | -5.77 |
| Tiziana Life Sciences | N/A | N/A | -$11.86 million | N/A | N/A |
Risk and Volatility
Tectonic Therapeutic has a beta of 3.71, indicating that its stock price is 271% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500.
Profitability
This table compares Tectonic Therapeutic and Tiziana Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tectonic Therapeutic | N/A | -27.11% | -25.88% |
| Tiziana Life Sciences | N/A | N/A | N/A |
Summary
Tectonic Therapeutic beats Tiziana Life Sciences on 6 of the 10 factors compared between the two stocks.
About Tectonic Therapeutic
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
About Tiziana Life Sciences
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
